AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression

AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression

Source: 
Fierce Pharma
snippet: 

Back in December, Roche unveiled a win for its cocktail of Tecentriq, Cotellic and Zelboraf in patients with BRAF V600-mutated melanoma. And details of that win are here.

In a phase 3 study to be presented virtually at the American Association for Cancer Research annual meeting, adding Tecentriq to the targeted melanoma drugs decreased the risk of disease progression or death by 22% versus the Cotellic and Zelboraf combo alone.